IN THE CLAIMS

Please amend the claims as follows:

Claims 1-8: (Canceled).

9. (Currently Amended): A method for reducing alleviating a symptom from

lipopolysaccharide-induced inflammation resulting from infection by bacteria which produce

lipopolysaccharide, comprising administering to a person orally or parenterally, prior to the

infection by the bacteria, an effective amount of human-type lactoferrin for a time and under

conditions effective to reduce alleviate said symptom, wherein said symptom is accumulation

of body fluid containing albumin in the abdominal cavity at the inflammatory site.

10. (Previously Presented): The method according to claim 9, wherein the effective

amount is 0.1 to 20 mg/kg of body weight/day in intravenous injection.

11. (Previously Presented): The method according to claim 10, wherein the effective

amount is 0.5 to 10 mg/kg of body weight/day.

12. (Previously Presented): The method according to claim 9, wherein the effective

amount is 1 to 200 mg/kg of body weight/day in intraperitoneal administration.

13. (Previously Presented): The method according to claim 9, wherein the effective

amount is 5 to 1000 mg/kg of body weight/day in oral administration.

2

Reply to Office Action of March 28, 2007

14. (Previously Presented): The method according to claim 13, wherein the effective

amount is 20 to 1000 mg/kg of body weight/day.

15. (Currently Amended): A method for <u>reducing alleviating</u> a symptom from

lipopolysaccharide-induced inflammation resulting from infection by bacteria which produce

lipopolysaccharide, comprising administering to a person orally or parenterally, prior to the

infection by the bacteria, an effective amount of human-type lactoferrin for a time and under

conditions effective to reduce alleviate said symptom, wherein said symptom is accumulation

of albumin at in the abdominal cavity the inflammatory site.

16. (Previously Presented): The method according to claim 15, wherein the effective

amount is 0.1 to 20 mg/kg of body weight/day in intravenous injection.

17. (Previously Presented): The method according to claim 16, wherein the effective

amount is 0.5 to 10 mg/kg of body weight/day.

18. (Previously Presented): The method according to claim 15, wherein the effective

amount is 1 to 200 mg/kg of body weight/day in intraperitoneal administration.

19. (Previously Presented): The method according to claim 15, wherein the effective

amount is 5 to 1000 mg/kg of body weight/day in oral administration.

20. (Previously Presented): The method according to claim 19, wherein the effective

amount is 20 to 1000 mg/kg of body weight/day.

3

Application No. 10/073,297 Reply to Office Action of March 28, 2007

Claims 21-32: (Canceled).

33. (Previously Presented) The method of Claim 9, wherein the lactoferrin is administered in the form of a tablet.

34. (Previously Presented) The method of Claim 15, wherein the lactoferrin is administered in the form of a tablet.

Claim 35: (Canceled).

36. (Previously Presented) The method of Claim 9, wherein the lactoferrin is administered parenterally.

37. (Previously Presented) The method of Claim 15, wherein the lactoferrin is administered parenterally.

Claim 38: (Canceled).

- 39. (Previously Presented) The method of Claim 9, wherein the lactoferrin is administered intravenously, intramucosally, percutaneously or intraperitoneally.
- 40. (Previously Presented) The method of Claim 15, wherein the lactoferrin is administered intravenously, intramucosally, percutaneously or intraperitoneally.
 - 41. (Canceled).